Physician profile
Anna E Barrickman
NPI 1891217527
$1,801.73
in general payments reported to CMS, 2019-2025
26 companies · $710 in 2025
The $710 reported for 2025 was more than what 80% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $9.91 · 2022: $14.08 · 2023: $470 · 2024: $598 · 2025: $710.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,778.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,777.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $460.12 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $379.10 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $131.53 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $87.62 | 2024-2025 | Caplyta |
| Abbott Laboratories | $82.98 | 2023-2025 | Freestyle Libre 3, Proclaim, Freestyle Libre |
| Abbvie INC. | $63.42 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $62.10 | 2024-2025 | Trintellix |
| Dynavax Technologies Corporation | $51.50 | 2024-2025 | Heplisav-B |
| Glaxosmithkline, LLC. | $47.90 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $46.31 | 2023-2024 | Otezla, Repatha |
| Exact Sciences Corporation | $44.06 | 2024-2025 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $39.36 | 2024-2025 | Auvelity |
| Corcept Therapeutics | $38.42 | 2025 | Korlym |
| Abiomed | $33.91 | 2025 | |
| Boston Scientific Corporation | $32.77 | 2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.50 | 2024 | Jardiance, Synjardy |
| Medtronic, INC. | $24.57 | 2025 | Minimed 780g |
| Regeneron Healthcare Solutions, INC. | $22.75 | 2024 | Evkeeza |
| Insulet Corporation | $21.13 | 2025 | Omnipod |
| Avvisto Therapeutics, LLC | $18.42 | 2025 | Cycloset |
| Phathom Pharmaceuticals, INC. | $17.95 | 2025 | Voquezna |
| Inspire Medical Systems, INC. | $14.90 | 2024 | Inspire |
| Astellas Pharma US INC | $14.45 | 2024 | Veozah |
| Novartis Pharmaceuticals Corporation | $14.08 | 2022 | |
| Merck Sharp & Dohme LLC | $13.97 | 2023 | Verquvo, Belsomra |
| Genentech USA, INC. | $9.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Barrickman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.